OneMedNet expands cardiovascular network with 85 new data sources.

OneMedNet Corporation has expanded its cardiovascular data network by adding 85 new centers and data sources, positioning it as a leading provider of cardiovascular Real-World data. Cardiovascular diseases are the leading cause of death globally, with an estimated $320 billion in annual direct healthcare costs and lost productivity in the US alone. OneMedNet's data network is ideal for pharmaceutical and insurance sectors, offering real-time, expansive data for drug developers.

OneMedNet Corporation (NASDAQ:ONMD) has significantly expanded its cardiovascular data network by adding 85 new centers and data sources, positioning itself as a leading provider of cardiovascular Real-World Data (RWD). This expansion comes at a critical time, as cardiovascular diseases (CVDs) remain the leading cause of death globally, accounting for approximately 19.8 million deaths in 2022 and an estimated $320 billion annually in direct healthcare costs and lost productivity in the United States alone [1].

The new data network includes de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG), offering life sciences companies, AI developers, and medical device manufacturers unprecedented scale and clinical depth. This expansion is particularly beneficial for pharmaceutical companies, which can leverage real-time, expansive data to gain deeper insights into disease progression, treatment responses, and outcomes. This information can fuel more efficient and evidence-based research and development (R&D), accelerating the development of novel therapeutics.

OneMedNet's strategic partnership with Circle Cardiovascular Imaging (Circle CVI) further underscores its commitment to the healthcare AI data market. The partnership enables Circle CVI to access OneMedNet's extensive real-world data network for AI model development, cardiac diagnostics, and treatment planning. This collaboration highlights OneMedNet's ability to meet the stringent requirements of healthcare AI innovation and regulatory standards [2].

The expanded network and strategic partnership position OneMedNet as a key player in the rapidly growing healthcare AI data market. As regulatory scrutiny of AI applications in healthcare intensifies, access to diverse, high-quality, properly de-identified real-world data becomes increasingly valuable. OneMedNet's focus on "regulatory-grade" data suggests its platform meets the stringent requirements needed for AI model validation in clinical settings.

Looking ahead, OneMedNet's focus on subscription-based revenue models and its ability to secure predictable cash flow through long-term partnerships like the one with Circle CVI indicate a promising growth trajectory. The company's ability to replicate this model with other healthcare technology partners could further solidify its market position and drive recurring revenue growth.

References:
[1] https://www.stocktitan.net/news/ONMD/one-med-net-initiates-new-subscription-revenue-model-in-partnership-qbi5vzi61cmp.html
[2] https://www.globenewswire.com/news-release/2025/08/20/3136331/0/en/OneMedNet-Adds-2-7M-Annual-Cardiovascular-Studies-Expanding-Network.html